BidaskClub upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a sell rating to a hold rating in a report published on Saturday.

A number of other analysts also recently commented on the stock. Zacks Investment Research upgraded shares of Seres Therapeutics from a hold rating to a buy rating and set a $9.25 price target on the stock in a research report on Wednesday, May 16th. ValuEngine upgraded shares of Seres Therapeutics from a sell rating to a hold rating in a research report on Wednesday, June 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. Seres Therapeutics presently has an average rating of Buy and a consensus target price of $17.89.

MCRB stock opened at $9.21 on Friday. Seres Therapeutics has a 52 week low of $6.65 and a 52 week high of $17.42. The company has a debt-to-equity ratio of 0.85, a current ratio of 3.60 and a quick ratio of 3.60.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Wednesday, May 9th. The biotechnology company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.06. Seres Therapeutics had a negative net margin of 277.79% and a negative return on equity of 150.44%. The company had revenue of $3.97 million for the quarter, compared to the consensus estimate of $3.00 million. analysts forecast that Seres Therapeutics will post -2.53 earnings per share for the current year.

In related news, CEO Roger Pomerantz sold 4,496 shares of the business’s stock in a transaction that occurred on Friday, June 29th. The shares were sold at an average price of $9.10, for a total value of $40,913.60. Following the sale, the chief executive officer now directly owns 249,864 shares in the company, valued at approximately $2,273,762.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John G. Aunins sold 14,279 shares of the business’s stock in a transaction that occurred on Friday, June 15th. The stock was sold at an average price of $8.57, for a total transaction of $122,371.03. Following the completion of the sale, the insider now owns 170,206 shares in the company, valued at $1,458,665.42. The disclosure for this sale can be found here. Insiders sold a total of 143,579 shares of company stock worth $1,295,535 over the last quarter. Insiders own 37.10% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Alps Advisors Inc. raised its holdings in shares of Seres Therapeutics by 21.0% in the 1st quarter. Alps Advisors Inc. now owns 54,359 shares of the biotechnology company’s stock worth $399,000 after purchasing an additional 9,448 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of Seres Therapeutics in the 4th quarter worth approximately $143,000. Wells Fargo & Company MN raised its holdings in shares of Seres Therapeutics by 107.2% in the 4th quarter. Wells Fargo & Company MN now owns 29,183 shares of the biotechnology company’s stock worth $296,000 after purchasing an additional 15,097 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Seres Therapeutics by 72.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 49,530 shares of the biotechnology company’s stock worth $502,000 after purchasing an additional 20,839 shares in the last quarter. Finally, Two Sigma Advisers LP raised its holdings in shares of Seres Therapeutics by 153.6% in the 4th quarter. Two Sigma Advisers LP now owns 35,500 shares of the biotechnology company’s stock worth $360,000 after purchasing an additional 21,500 shares in the last quarter. Institutional investors and hedge funds own 79.53% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.